Mediclinic Group
An international private hospital group operating healthcare facilities across Southern Africa, Switzerland and the United Arab Emirates.
Last updated October 16, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Mediclinic Group is an international private healthcare organization whose principal business has been the ownership and operation of hospitals, clinics and related medical facilities. Its operating footprint has centered on South Africa and Namibia, Switzerland through the Hirslanden network, and the United Arab Emirates through its Dubai-based healthcare operations. The group has historically combined hospital management with specialist clinical services, surgery, diagnostics, inpatient care and related outpatient provision. The business was established in Stellenbosch, South Africa, in 1983. Dr Edwin Hertzog was commissioned by the Rembrandt Group, now known as Remgro, to examine whether privately operated hospitals could be commercially viable. The study led to the creation of Mediclinic. By 1986, the developing group was operating four hospitals, had three more under construction, and was listed on the Johannesburg Stock Exchange. That South African listing gave Mediclinic a platform for expansion and helped establish it as one of the country’s significant private hospital operators. Mediclinic’s international strategy accelerated in the 2000s. In 2006 it agreed to acquire a controlling interest in Emirates Healthcare in Dubai, which at the time owned one hospital, held rights to develop two further hospitals in Dubai Healthcare City, and operated five clinics. In 2007 Mediclinic acquired Hirslanden, described as Switzerland’s largest private hospital group, for approximately CHF2.54 billion. Hirslanden became the group’s major European operating platform and materially expanded Mediclinic’s exposure to high-end private hospital care, specialist medicine and international patients. The group later developed a substantial United Kingdom connection. In 2015 it acquired a 29.9% interest in Spire Healthcare, a listed UK private healthcare provider. In the same year Mediclinic announced a reverse merger with Al Noor Hospitals in the United Arab Emirates. The transaction was completed in February 2016, after which the combined business began trading on the London Stock Exchange. This structure made Mediclinic a cross-listed international healthcare company while preserving its Johannesburg listing. Mediclinic’s corporate profile subsequently included hospital operations in several regulated healthcare systems and a minority investment in Spire Healthcare. The model relied on clinical scale, hospital networks, specialist physicians, quality systems and relationships with private insurers and self-paying patients. Its businesses served both routine and complex care, including surgery, medical specialties, emergency services, diagnostics and rehabilitation-related services, although the exact mix varied by country and facility. The company also attracted public scrutiny. In 2021 its South African operation was criticized after it emerged that Wouter Basson, a controversial physician and former head of South Africa’s chemical and biological weapons program, was working at one of its Western Cape facilities. The controversy concerned the doctor’s employment and professional history rather than a disclosed failure of Mediclinic’s hospital network. In August 2022 Mediclinic accepted a takeover proposal valued at approximately £3.7 billion from a South African consortium including Remgro and Mediterranean Shipping Company. Regulatory steps continued into 2023, and the company confirmed in May that approval from the South African Reserve Bank had been obtained, enabling completion. Mediclinic consequently ceased to be a London-listed company. The transaction changed the group from a publicly traded international holding company into a privately owned healthcare group associated with the consortium. The reference material also describes a proposed 2026 restructuring under which Remgro would acquire full ownership of Mediclinic Southern Africa for approximately R16.2 billion, while the Swiss Hirslanden business would be sold to IHL. The proposal would separate the Southern African and Swiss operations geographically while retaining joint interests in the Middle East and United Kingdom. At the time described, the transaction was awaiting regulatory approval in South Africa and Switzerland. Accordingly, Mediclinic’s current corporate configuration may continue to change, and the legal ownership of each regional business should be verified against later company announcements. In August 2022 Mediclinic accepted a takeover offer from a South African consortium including Remgro and Mediterranean Shipping Company, valued at approximately £3.7 billion. Regulatory processes continued into 2023, and in May the company confirmed it had received approval from the South African Reserve Bank, allowing the transaction to complete. Mediclinic therefore ceased to be a London-listed company. The deal transformed the group from a publicly listed international holding company into a privately held healthcare group associated with the consortium. The reference material also describes a proposed 2026 restructuring under which Remgro would acquire full ownership of Mediclinic Southern Africa for approximately R16.2 billion, while the Swiss Hirslanden business would be sold to IHL; the parties would retain joint interests in the Middle East and UK. The arrangement was awaiting regulatory approval in South Africa and Switzerland when reported, so its final completion and structure remain subject to verification.
History
Mediclinic began in 1983 in Stellenbosch after Dr Edwin Hertzog conducted a feasibility study for the Rembrandt Group on the commercial prospects of private hospitals. The project developed into a hospital company with four operating hospitals and three under construction by 1986, when Mediclinic listed on the Johannesburg Stock Exchange. The group expanded beyond South Africa during the 2000s. In 2006 it agreed to take control of Emirates Healthcare in Dubai, gaining an existing hospital, development rights in Dubai Healthcare City and a network of clinics. In 2007 Mediclinic acquired Hirslanden, Switzerland’s largest private hospital group according to the reference material, for approximately CHF2.54 billion. The acquisition became the foundation of Mediclinic’s Swiss operations and substantially diversified the group geographically. Mediclinic strengthened its UK presence in 2015 by purchasing a 29.9% stake in Spire Healthcare. It also announced a reverse merger with Al Noor Hospitals, an important UAE healthcare operator. Completion took place on 15 February 2016, and the enlarged business started trading on the London Stock Exchange on 16 February. Mediclinic retained its Johannesburg listing while operating as an international hospital group across Southern Africa, Switzerland and the Middle East. In 2020 the founder stepped down and Dame Inga Beale became chair. The following year, Mediclinic’s South African operation drew criticism connected with the employment of Wouter Basson at a Western Cape facility. Basson’s earlier role in South Africa’s chemical and biological weapons program made the appointment a subject of public controversy. Mediclinic accepted a consortium takeover in August 2022. The proposed buyers included Remgro and Mediterranean Shipping Company, and the reported value was approximately £3.7 billion. Approval from the South African Reserve Bank was confirmed in May 2023, enabling completion. Mediclinic was then removed from the London Stock Exchange, ending its period as a London-listed international healthcare company while its regional hospital businesses continued operating. The supplied reference material further reports an April 2026 agreement involving a geographic separation of the group. Under the proposed arrangement, Remgro would acquire full ownership of Mediclinic Southern Africa for about R16.2 billion, while IHL would acquire the Swiss Hirslanden Private Hospital Group from Mediclinic Holdings. The parties would retain joint interests in the Middle East and UK. The proposal was still awaiting regulatory approval in South Africa and Switzerland when described, so its final implementation and effect on the Mediclinic brand require later verification.
- 2023
Takeover approved and London listing ends
[1]South African Reserve Bank approval allows the consortium transaction to complete, ending Mediclinic’s London Stock Exchange listing.
- 2022
Takeover accepted
[1]Mediclinic accepts a consortium takeover proposal valued at approximately £3.7 billion.
- 2020
Change in chair
[1]Founder Dr Edwin Hertzog steps down and Dame Inga Beale becomes chair.
- 2016
Al Noor merger and London listing
[1]The Al Noor Hospitals reverse merger completes in February, and the combined business begins trading on the London Stock Exchange.
- 2015
Investment in Spire Healthcare
[1]Mediclinic acquires a 29.9% interest in UK private healthcare group Spire Healthcare.
- 2007
Acquisition of Hirslanden
[1]Mediclinic acquires Swiss private hospital group Hirslanden for approximately CHF2.54 billion.
- 2006
Entry into Dubai healthcare
[1]Mediclinic agrees to acquire a controlling interest in Emirates Healthcare, expanding into hospitals and clinics in the United Arab Emirates.
- 1986
Johannesburg Stock Exchange listing
[1]Mediclinic lists on the JSE after developing an initial network of operating and planned hospitals.
- 1983
Mediclinic is founded in Stellenbosch
[1]Dr Edwin Hertzog’s feasibility work for the Rembrandt Group leads to the creation of Mediclinic as a private hospital venture.
Products and positioning
A multinational private hospital operator positioned around specialist clinical care, hospital networks, medical quality and access to advanced treatment in several established private healthcare markets.
Hospital services · 1983
Private hospital care
Mediclinic’s core offering is privately delivered hospital care, including planned and emergency admissions, inpatient treatment, surgery, specialist consultations and discharge-related care. The service is delivered through regional hospital networks rather than as a single standardized product, with clinical scope determined by each facility and local healthcare regulation.
Clinical services
Specialist and surgical services
The group’s hospitals provide specialist medical and surgical treatment, supported by operating theatres, intensive or acute care capabilities, diagnostics and specialist physicians. The precise specialties differ between South African, Swiss and Middle Eastern facilities, but the offering is aimed at complex as well as routine private medical care.
Ambulatory healthcare · 2006
Outpatient and clinic services
Mediclinic’s historical operating portfolio has included outpatient clinics and ambulatory services, particularly through its UAE activities. These facilities complement hospitals by providing consultations, diagnostics, follow-up care and selected treatments without requiring overnight admission.
Swiss private healthcare · 2007
Hirslanden hospital network
Hirslanden is Mediclinic’s Swiss hospital platform, acquired in 2007. It provides private hospital and specialist medical services in Switzerland and has been one of the most strategically important assets in Mediclinic’s international portfolio.
Controversies
2021
Controversy over Wouter Basson’s employment
Mediclinic’s South African business was criticized after reports that Wouter Basson was working at a Western Cape facility. Basson’s prior leadership of South Africa’s chemical and biological weapons program made his association with the facility controversial.
Brand decisions
2026
Proposed geographic separation of regional operationsStrategyBackground
The proposed transaction would align ownership of Mediclinic’s Southern African and Swiss operations with separate strategic owners.
Action taken
Remgro agreed to acquire full ownership of Mediclinic Southern Africa, while Mediclinic Holdings would sell Hirslanden to IHL; the parties would retain joint interests in the Middle East and UK.
Aftermath
The arrangement was awaiting regulatory approval in South Africa and Switzerland when reported, so its final completion and structure remain subject to verification.
Proposed Mediclinic Southern Africa transaction value. R16.2 billion (April 2026)
2022
Accept consortium takeoverM&ABackground
The board accepted a proposal to take Mediclinic private after the company had operated as a cross-listed international healthcare group.
Action taken
Mediclinic accepted a takeover offer from a South African consortium including Remgro and Mediterranean Shipping Company.
Aftermath
Regulatory approval was confirmed in 2023 and the London listing ended.
Takeover value. Approximately £3.7 billion (2022)
2015
Invest in Spire HealthcareM&ABackground
Mediclinic expanded its exposure to the UK private healthcare sector.
Action taken
Mediclinic acquired a 29.9% interest in Spire Healthcare.
Aftermath
The investment gave Mediclinic a significant minority position in a UK listed private healthcare group.
2015
Announce reverse merger with Al Noor HospitalsM&ABackground
Mediclinic pursued a larger and more integrated UAE healthcare platform.
Action taken
The company announced a reverse merger with Al Noor Hospitals, completed on 15 February 2016.
Aftermath
The combined business began trading on the London Stock Exchange on 16 February 2016.
2007
Acquire HirslandenM&ABackground
Mediclinic sought international scale and a substantial presence in a developed private healthcare market.
Action taken
The group acquired Swiss private hospital operator Hirslanden.
Aftermath
Hirslanden became Mediclinic’s principal Swiss operating platform.
Acquisition consideration. CHF2.54 billion (2007)
Sources1 sources
Cite this profile: Cite the canonical profile. /brand-wiki/mediclinic-group · Editorial policy · How profiles are compiled